David M Mannino1, Matthew M Reichert, Kourtney J Davis. 1. Division of Pulmonary and Critical Care Medicine, University of Kentucky Medical Center, 800 Rose Street, MN 614, Lexington, KY 40536, USA. dmannino@uky.edu
Abstract
RATIONALE: Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality. OBJECTIVES: To determine risk factors for and outcomes of rapid lung function decline in a cohort of adults in the United States. METHODS: We analyzed data from 15,536 adults aged 44-66 yr in the Atherosclerosis Risk in Communities study. We used Cox proportional hazard models to determine the risk of rapid lung function decline at 3 yr on mortality and COPD hospitalizations over the subsequent 8 yr. MEASUREMENTS AND MAIN RESULTS: Of those in the baseline cohort, 13,756 (88.5%) had spirometry at the Year 3 visit. The strongest risk factors for not having a follow-up spirometry were as follows: having Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 disease at baseline (adjusted odds ratio [OR] 2.8; 95% confidence interval [CI], 2.1-3.8), being black (adjusted OR, 2.4; 95% CI, 2.1-2.7), and being a current smoker (adjusted OR, 1.8; 95% CI, 1.5-2.0). Participants with GOLD stage 3 or 4 disease were also more likely to be in the most rapidly declining lung function quartile (adjusted OR, 3.7; 95% CI, 2.7-5.0). Overall, participants with the most rapidly declining lung function had a modestly increased risk of death (adjusted hazard ratio, 1.4; 95% CI, 1.2-1.7) and time to a COPD-related hospitalization (adjusted hazard ratio, 1.4; 95% CI, 1.2-1.8). CONCLUSION: Rapid lung function decline was independently associated with a modest increased risk of COPD hospitalizations and deaths.
RATIONALE: Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality. OBJECTIVES: To determine risk factors for and outcomes of rapid lung function decline in a cohort of adults in the United States. METHODS: We analyzed data from 15,536 adults aged 44-66 yr in the Atherosclerosis Risk in Communities study. We used Cox proportional hazard models to determine the risk of rapid lung function decline at 3 yr on mortality and COPD hospitalizations over the subsequent 8 yr. MEASUREMENTS AND MAIN RESULTS: Of those in the baseline cohort, 13,756 (88.5%) had spirometry at the Year 3 visit. The strongest risk factors for not having a follow-up spirometry were as follows: having Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 disease at baseline (adjusted odds ratio [OR] 2.8; 95% confidence interval [CI], 2.1-3.8), being black (adjusted OR, 2.4; 95% CI, 2.1-2.7), and being a current smoker (adjusted OR, 1.8; 95% CI, 1.5-2.0). Participants with GOLD stage 3 or 4 disease were also more likely to be in the most rapidly declining lung function quartile (adjusted OR, 3.7; 95% CI, 2.7-5.0). Overall, participants with the most rapidly declining lung function had a modestly increased risk of death (adjusted hazard ratio, 1.4; 95% CI, 1.2-1.7) and time to a COPD-related hospitalization (adjusted hazard ratio, 1.4; 95% CI, 1.2-1.8). CONCLUSION: Rapid lung function decline was independently associated with a modest increased risk of COPD hospitalizations and deaths.
Authors: Andreas M Neophytou; Sadie Costello; Sally Picciotto; Elizabeth M Noth; Sa Liu; Liza Lutzker; John R Balmes; Katharine Hammond; Mark R Cullen; Ellen A Eisen Journal: Occup Environ Med Date: 2019-10-14 Impact factor: 4.402
Authors: Theodore G Liou; Eric P Elkin; David J Pasta; Joan R Jacobs; Michael W Konstan; Wayne J Morgan; Jeffrey S Wagener Journal: J Cyst Fibros Date: 2010-05-14 Impact factor: 5.482
Authors: Penelope Baughman; Jacob L Marott; Peter Lange; Christopher J Martin; Anoop Shankar; Edward L Petsonk; Eva Hnizdo Journal: Eur J Epidemiol Date: 2012-12-14 Impact factor: 8.082
Authors: Catherine H Miele; Matthew R Grigsby; Trishul Siddharthan; Robert H Gilman; J Jaime Miranda; Antonio Bernabe-Ortiz; Robert A Wise; William Checkley Journal: Thorax Date: 2018-07-30 Impact factor: 9.139
Authors: Jacob Louis Marott; Truls Sylvan Ingebrigtsen; Yunus Çolak; Jørgen Vestbo; Peter Lange Journal: Am J Respir Crit Care Med Date: 2020-07-15 Impact factor: 21.405
Authors: Teemu J Niiranen; Danielle M Enserro; Martin G Larson; Ramachandran S Vasan Journal: J Gerontol A Biol Sci Med Sci Date: 2019-10-04 Impact factor: 6.053
Authors: R Perez-Padilla; W M Vollmer; J C Vázquez-García; P L Enright; A M B Menezes; A S Buist Journal: Int J Tuberc Lung Dis Date: 2009-03 Impact factor: 2.373